FibroGen, Inc

FGEN Real Time Price USD

N/A

...

Overview

Financials

Forecast

Insiders

Institutions

Government

Ownership

News

Income

Balance Sheet

Cash Flow

Revenue Breakdown

Congress Trading

Recent trades of FGEN by members of U.S. Congress

No Congress Trading data for this ticker

Congress Trading Dashboard

FGEN Stock Insider Trading Activity

Name	Type	Shares	Price	Shares Held	Date	Reported

FGEN Stock Institutional Owners

Investor	Shares	Change in Shares	Market Value	Date	Reported

FGEN Derivatives Institutional Owners

Investor	Type	Shares	Change in Shares	Market Value	Date	Reported

Whale Activity

Recently reported changes by institutional investors

No Whale Activity for this ticker

Institutional Holdings Dashboard

Insider Trading

Quarterly net insider trading by FGEN's directors and management

Corporate Lobbying

Government lobbying spending instances

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard

Corporate Lobbying

Estimated quarterly lobbying spending

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard

Revenue Breakdown

FGEN Revenue by Segment or Geography

By Segment

By Geography

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard

FGEN Income Statement

FGEN Balance Sheet

FGEN Cash Flow

U.S. Patents

New patents grants

Patent Title: Enhanced erythropoiesis and iron metabolism Jun. 20, 2023
Patent Title: Enhanced erythropoiesis and iron metabolism Jun. 20, 2023
Patent Title: Methods for treatment of motor neuron diseases Apr. 12, 2022
Patent Title: Nitrogen-containing heteroaryl compounds and methods of use thereof Jan. 25, 2022
Patent Title: Enhanced erythropoiesis and iron metabolism Feb. 23, 2021
Patent Title: Enhanced erythropoiesis and iron metabolism Jan. 19, 2021
Patent Title: Enhanced erythropoiesis and iron metabolism Jan. 05, 2021
Patent Title: Pharmaceutical formulations of a hif hydroxylase inhibitor Sep. 08, 2020
Patent Title: Nitrogen-containing heteroaryl compounds and methods of use thereof May. 12, 2020
Patent Title: Methods for treating idiopathic pulmonary fibrosis Feb. 11, 2020
Patent Title: Crystalline forms of a prolyl hydroxylase inhibitor Apr. 30, 2019
Patent Title: Crystalline forms of a prolyl hydroxylase inhibitor Nov. 06, 2018
Patent Title: Nitrogen-containing heteroaryl compounds and methods of use thereof Oct. 09, 2018
Patent Title: Methods for treating idiopathic pulmonary fibrosis Aug. 07, 2018
Patent Title: Enhanced erythropoiesis and iron metabolism Mar. 20, 2018
Patent Title: Crystalline forms of a prolyl hydroxylase inhibitor Mar. 20, 2018
Patent Title: Compounds and methods for treatment of stroke Oct. 03, 2017
Patent Title: Process for making isoquinoline compounds Jul. 18, 2017
Patent Title: Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase Jul. 04, 2017
Patent Title: Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid May. 09, 2017
Patent Title: Therapeutic method for pancreatic cancer Apr. 25, 2017
Patent Title: Crystalline forms of a prolyl hydroxylase inhibitor Apr. 11, 2017
Patent Title: Treatment method for lung remodeling diseases Mar. 07, 2017
Patent Title: Methods for treating idiopathic pulmonary fibrosis Nov. 01, 2016
Patent Title: 4-hydroxy-isoquinoline compounds as hif hydroxylase inhibitors Aug. 09, 2016
Patent Title: Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity Jul. 12, 2016
Patent Title: Crystalline forms of a prolyl hydroxylase inhibitor Jun. 21, 2016
Patent Title: Process for making isoquinoline compounds May. 17, 2016
Patent Title: Nitrogen-containing heteroaryl compounds and methods of use thereof May. 17, 2016
Patent Title: Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase Mar. 01, 2016
Patent Title: Cyanoisoquinoline compounds and methods of use thereof Nov. 03, 2015
Patent Title: Thiochromene derivatives as hif hydroxylase inhibitors Oct. 06, 2015
Patent Title: Connective tissue growth factor antisense oligonucleotides Aug. 25, 2015
Patent Title: Crystalline forms of a prolyl hydroxylase inhibitor Aug. 25, 2015
Patent Title: Therapeutic method Aug. 11, 2015
Patent Title: Connective tissue growth factor antibodies May. 19, 2015
Patent Title: Thienopyridine compounds, and methods of use thereof Apr. 07, 2015
Patent Title: Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity Feb. 10, 2015
Patent Title: Thiochromene derivatives as hif hydroxylase inhibitors Jan. 06, 2015
Patent Title: Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase Dec. 30, 2014
Patent Title: Nitrogen-containing heteroaryl compounds and methods of use thereof Dec. 23, 2014
Patent Title: Crystalline forms of a prolyl hydroxylase inhibitor Nov. 11, 2014
Patent Title: Treatments for pancreatic cancer metastases Oct. 21, 2014
Patent Title: Connective tissue growth factor antisense oligonucleotides Aug. 12, 2014
Patent Title: Methods for treatment of muscular dystrophy Jul. 08, 2014
Patent Title: Nitrogen-containing heteroaryl compounds and methods of use thereof Jul. 01, 2014
Patent Title: Cyanoisoquinoline compounds and methods of use thereof Jun. 24, 2014
Patent Title: Treatments for cancer May. 20, 2014
Patent Title: Thienopyridine compounds, and methods of use thereof Apr. 22, 2014
Patent Title: Enhanced erythropoiesis and iron metabolism Jan. 14, 2014

Government Contracts

Federal grants, loans, and purchases

No Government Contracts for this ticker

Government Contracts Dashboard

Government Contracts

Estimated quarterly amount awarded from public contracts

No recent Government Contracts for this ticker

Government Contracts Dashboard

FGEN News

Recent insights relating to FGEN

CNBC Recommendations

Recent picks made for FGEN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in FGEN

FGEN Analyst Ratings

FGEN Stock Forecasts

...

... Highest Price Target
... Median Price Target
... Lowest Price Target

FGEN Analyst Forecasts

Analyst	Firm	Current	Previous	Date

Frequently Asked Questions

Is $FGEN stock a Buy, Sell, or Hold?
What is the price target for $FGEN stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

FGEN Top Shareholders

Shareholder	Shares Held

FGEN Options Owners

Shareholder	Security	Underlying Shares

Frequently Asked Questions

Who owns $FGEN stock?
Who owns the most shares of $FGEN stock?
What funds own $FGEN stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

FGEN Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.

Score Breakdown

Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.